Corvus Pharmaceuticals, Inc.
Symbol: CRVS (NASDAQ)
7.25
▲ (0.91%) 0.065
Company Description:
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Key Stats
- Today's Open: $7.2
- Today's High: $7.409
- Today's Low: $7.095
- Today's Volume: 124.94K
- Yesterday Close: $7.18
- Yesterday High: $7.43
- Yesterday Low: $6.81
- Yesterday Volume: 873.27K
- Last Min Volume: 109
- Last Min High: $7.245
- Last Min Low: $7.245
- Last Min VWAP: $7.245
Company Profile
- Name: Corvus Pharmaceuticals, Inc.
- Website: https://www.corvuspharma.com
- Listed Date: 2016-03-23
- Location: BURLINGAME, CA
- Market Status: Active
- CIK Number: 0001626971
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $536.50M
- Round Lot: 100
- Outstanding Shares: 74.51M
- Asset Type: CS
RECENT FILINGS FOR CRVS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-17 | SCHEDULE 13G | View |
| 2025-10-06 | 4 | View |
| 2025-10-06 | 3 | View |
| 2025-10-02 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-01 | 4 | View |
| 2025-07-01 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-13 | 8-K | View |
| 2025-06-06 | 4 | View |
| 2025-06-04 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-14 | SCHEDULE 13D/A | View |
| 2025-05-09 | 4 | View |
| 2025-05-08 | S-8 | View |
Latest News on CRVS